Israel’s Bonus Biogroup (TLV:BONS) said today that it successfully injected its lab-grown, semi-liquid bone graft into the jaws of 11 people in an early stage clinical trial evaluating bone loss repair. The company is presenting its results at the International Conference on Oral & Maxillofacial Surgery in Spain today.
The material is grown in a lab from a patient’s own fat cells and then injected into the voids of problematic bones in the jaw. Over the course of a few months, the material hardens and merges with existing bones to fill out the jaw.
The transplant “was 100% successful in all 11 patients,” Ora Burger, the VP of regulation affairs, told Reuters. “Now we are going to conduct a clinical study in the extremities, long bones.”
CEO Shai Meretski previously founded Pluristem Therapeutics, an advanced Israeli biomedical company that works with stem cells.
“For the first time worldwide, reconstruction of deficient or damaged bone tissue is achievable by growing viable human bone graft in a laboratory, and transplanting it back to the patient in a minimally invasive surgery via injection,”Meretski told the news outlet.
The company has raised $14 million and plans to dual list on NSDQ soon.
The post Lab-grown bone shows 100% success rate in small, early study appeared first on MassDevice.
from MassDevice http://ift.tt/2gtXKhp
Cap comentari:
Publica un comentari a l'entrada